Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to -$295,000.

  • Ani Pharmaceuticals' Other Operating Expenses fell 100.37% to -$295,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $291.3 million, marking a year-over-year increase of 3.45%. This contributed to the annual value of $312.2 million for FY2024, which is 32.71% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Other Operating Expenses stood at -$295,000, which was down 100.30% from $99.2 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Other Operating Expenses' 5-year high stood at $108.6 million during Q4 2024, with a 5-year trough of -$350,000 in Q4 2021.
  • Moreover, its 3-year median value for Other Operating Expenses was $70.6 million (2023), whereas its average is $67.7 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first spiked by 15,081.14% in 2022, then crashed by 100.37% in 2025.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Other Operating Expenses stood at -$350,000 in 2021, then spiked by 15,081.14% to $52.4 million in 2022, then skyrocketed by 34.64% to $70.6 million in 2023, then surged by 53.81% to $108.6 million in 2024, then crashed by 100.37% to -$295,000 in 2025.
  • Its Other Operating Expenses was -$295,000 in Q3 2025, compared to $99.2 million in Q2 2025 and $83.8 million in Q1 2025.